This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-05. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
=== Poroelasticity === Poroelasticity is a characteristic of materials related to the migration of solvent through a porous material and the concurrent deformation that occurs. Poroelasticity in hydrated materials such as hydrogels occurs due to friction between the polymer and water as the water moves through the porous matrix upon compression. This causes a decrease in water pressure, which adds additional stress upon compression. Similar to viscoelasticity, this behavior is time dependent, thus poroelasticity is dependent on compression rate: a hydrogel shows softness upon slow compression, but fast compression makes the hydrogel stiffer. This phenomenon is due to the friction between the water and the porous matrix is proportional to the flow of water, which in turn is dependent on compression rate. Thus, a common way to measure poroelasticity is to do compression tests at varying compression rates. Pore size is an important factor in influencing poroelasticity. The Kozeny–Carman equation has been used to predict pore size by relating the pressure drop to the difference in stress between two compression rates. Poroelasticity is described by several coupled equations, thus there are few mechanical tests that relate directly to the poroelastic behavior of the material, thus more complicated tests such as indentation testing, numerical or computational models are utilized. Numerical or computational methods attempt to simulate the three dimensional permeability of the hydrogel network.
=== Research === He started his research in the chemistry of natural products. At Washington State University he established early steps in the metabolism of d-neomethyl-α-D-glucoside in pipermint (Mentha piperita) rhizomes via in vivo studies. Bhushan developed a de novo method for direct resolution of certain racemates by liquid chromatography. Later, the approach was applied for direct enantioseparation of several active pharmaceutical ingredients (APIs). It is now an established approach in literature. 1994 onwards, the method was extended to such resolutions by ligand exchange principle. The method is of significant importance to pharmaceutical industry and analytical laboratories associated with regulatory agencies for determination and control of enantiomeric purity (and isolation of native enantiomers) of a variety of APIs since many of them are marketed and administered as racemic mixture while only one enantiomer is therapeutically useful. Bhushan supervised the Ph.D. theses of > 30 scholars and has published more than 270 research papers.
The Cerebras CS-2 system can train multibillion-parameter natural-language-processing (NLP) models including GPT-3XL 1.3 billion models, as well as GPT-J 6B, GPT-3 13B, and GPT-NeoX 20B with reduced software complexity and infrastructure. In August 2022, the Computer History Museum in Mountain View, California unveiled a new display featuring the WSE-2, named "The Biggest Chip In the World". Also in August 2022, Cerebras opened an office in Bangalore, India. In September 2022, Cerebras announced that it can patch its chips together to create what would be the largest-ever computing cluster for AI computing. A Wafer-Scale Cluster can connect up to 192 CS-2 AI systems into a cluster, while a cluster of 16 CS-2 AI systems can create a computing system with 13.6 million cores for natural-language processing. It uses data parallelism to train. In October 2022, Sandia National Laboratories of the National Nuclear Security Administration began using the CS-2 in nuclear stockpile stewardship computing, to determine if nuclear weapons will work as intended. In November 2022, Cerebras unveiled the Andromeda supercomputer, which combines 16 WSE-2 chips into one cluster with 13.5 million AI-optimized cores, delivering up to 1 exaflop of AI computing horsepower, or at least one quintillion (1018) operations per second. The entire system consumes 500 kW, which was a drastically lower amount than somewhat-comparable GPU-accelerated supercomputers.
Sources: en.wikipedia.org
retinal + NADH + H+ ⇌ retinol + NAD+ retinol + NAD+ ⇌ retinal + NADH + H+ Retinal (also known as retinaldehyde) can be irreversibly converted to all-trans-retinoic acid by the action of retinal dehydrogenase
Richard A. Houghten is a heterocyclic organic chemist and founder of the journal Peptide Research, which was later merged with the International Journal of Peptide and Protein Research, to become the Journal of Peptide Research. His work mainly concerns peptide activity and pharmacology. He is the founder and president of the Torrey Pines Institute for Molecular Studies (TPIMS), a biomedical research institute. Houghten pioneered the "tea-bag" approach of producing peptides for pharmacological work. He is author of over five hundred scientific papers, 38 of which have been cited at least one hundred times. His h-index is over 60.
4-Hydroxymandelate is subsequently oxidized by hydroxymandelate oxidase (Hmo) to 4-hydroxylbenzoylformate, using FMN as a cofactor. Finally, 4-hydroxyphenylglycine transaminase (HpgT) transfers an ammonia moiety from a donor to 4-hydroxylbenzoylformate to form HPG. Several different molecules can serve as the nitrogen donor for the transamination, however, Hubbard et al suspect L-tyrosine to serve as the most efficient donor. By doing so, the following cycle is constructed:
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.